Literature DB >> 16263867

Memantine for treatment-resistant OCD.

Michael Poyurovsky, Ronit Weizman, Abraham Weizman, Lorrin Koran.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16263867     DOI： 10.1176/appi.ajp.162.11.2191-a

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  23 in total

Review 1.  Pharmacological treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; Michael H Bloch
Journal:  Psychiatr Clin North Am       Date:  2014-07-24

2.  Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion.

Authors:  Carolyn I Rodriguez; Amanda Levinson; Jordana Zwerling; Donna Vermes; Helen Blair Simpson
Journal:  J Clin Psychiatry       Date:  2016-05       Impact factor: 4.384

Review 3.  Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment.

Authors:  Christopher Pittenger; Michael H Bloch; Kyle Williams
Journal:  Pharmacol Ther       Date:  2011-09-22       Impact factor: 12.310

Review 4.  The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.

Authors:  Gabriele Sani; Giulia Serra; Giorgio D Kotzalidis; Silvia Romano; Stefano M Tamorri; Giovanni Manfredi; Matteo Caloro; C Ludovica Telesforo; Saverio S Caltagirone; Isabella Panaccione; Alessio Simonetti; Francesca Demontis; Gino Serra; Paolo Girardi
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

5.  Long-term outcome in adults with obsessive-compulsive disorder.

Authors:  Michael H Bloch; Christy Green; Stephen A Kichuk; Philip A Dombrowski; Suzanne Wasylink; Eileen Billingslea; Angeli Landeros-Weisenberger; Benjamin Kelmendi; Wayne K Goodman; James F Leckman; Vladimir Coric; Christopher Pittenger
Journal:  Depress Anxiety       Date:  2013-03-26       Impact factor: 6.505

6.  In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

Authors:  Mohammad Haghighi; Leila Jahangard; Hamid Mohammad-Beigi; Hafez Bajoghli; Hassan Hafezian; Alireza Rahimi; Hamid Afshar; Edith Holsboer-Trachsler; Serge Brand
Journal:  Psychopharmacology (Berl)       Date:  2013-03-23       Impact factor: 4.530

Review 7.  Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity.

Authors:  Dennis L Murphy; Pablo R Moya; Meredith A Fox; Liza M Rubenstein; Jens R Wendland; Kiara R Timpano
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

8.  Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.

Authors:  Christopher Pittenger; Michael H Bloch; Suzanne Wasylink; Eileen Billingslea; Ryan Simpson; Ewgeni Jakubovski; Ben Kelmendi; Gerard Sanacora; Vladimir Coric
Journal:  J Clin Psychiatry       Date:  2015-08       Impact factor: 4.384

9.  THE USE OF GLUTAMATE MODULATING DRUGS IN OBSESSIVE COMPULSIVE DISORDER.

Authors:  Frank P MacMaster; David R Rosenberg
Journal:  Child Adolesc Psychopharmacol News       Date:  2010-12

10.  Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder.

Authors:  Jonathan T Ting; Guoping Feng
Journal:  Curr Chem Genomics       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.